A Phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma

Cancer Investigation

Volumn 24, Issue 4, 2006, Pages 346-350

  Kulke, Matthew ^a   Muzikansky, Alona ^b   Clark, Jeffrey ^b   Enzinger, Peter ^a   Fidias, Panos ^b   Kinsella, Kate ^a   Michelini, Ann ^a   Fuchs, Charles ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Esophageal cancer; Gastric cancer; Vinorelbine

Indexed keywords

NAVELBINE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CARCINOMATOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG TOLERABILITY; DYSPNEA; EDEMA; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; ILEUS; LEUKOPENIA; MALE; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION RESPONSE; RASH; STOMACH ADENOCARCINOMA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE; VINBLASTINE;

EID: 33745294121     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900600705268     Document Type: Article

References (15)

1. Fuchs, C.; Mayer, R. Gastric carcinoma. N. Engl. J. Med. 1995, 333, 32-41.
2. Devesa, S.; Blot, W.; Frangioni, J. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998, 83, 2049-2053.
3. Jemal, A.; Tiwari, R.; Murray, T.; et al. Cancer Statistics, 2004. CA Cancer J. for Clinicians 2004, 54, 8-29.
4. Vogel, C.; O'Rourke, M.; Winer, E.; et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann. Oncol. 1999, 10, 397-402.
5. LeChevalier, T.; Pujol, J.; Douillard, Y. A European multicenter randomized study comparing Navelbine to Navelbine-Cisplatin vs Vindesine-Cisplatin in 612 patients with advanced non small cell lung cancer. Proc. ASCO 1992, 11, 289.
6. Bajetta, E.; Di Leo, A.; Biganzoli, L.; et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J. Clin. Oncol. 1996, 14 (9), 2546-2551.
7. Conroy, T.; Etienne, P.L.; Adenis, A.; et al. Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group. J. Clin. Oncol. 1996, 14 (1), 164-170.
8. Gridelli, C. The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist 2001, 6 (Suppl 1), 4-7.
9. Gasco, M.; Gardin, G.; Repetto, L.; Campora, E.; Rosso, R. Vinorelbine as palliative therapy in advanced breast cancer. Anticancer Res. 1997, 17 (2B), 1431-1433.
10. Kaplan, E.; Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1959, 53, 457-481.
11. Webb, A.; Cunningham, D.; Scarffe, J.; et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advances esophagogastric cancer. J. Clin. Oncol. 1997, 15, 261-267.
12. Boku, N.; Ohtsu, A.; Shimada, Y.; et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J. Clin. Oncol. 1999, 17, 319-323.
13. Al-Batran, S.; Atmaca, A.; Hegewisch-Becker, S.; et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J. Clin. Oncol. 2004, 22, 658-663.
14. Louvet, C.; Andre, T.; Tigaud, J.; et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J. Clin. Oncol. 2002, 20, 4543-4548.
15. Moiseyenko, V.; Ajani, J.; Tjulandin, S.; et al. Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma. Proc. ASCO 2005, 24, A4002.